Sees revenue $520M-$542M, consensus $535.11M. Sees Cortrophin Gel net revenue $170M-$180M. Sees adjusted non-GAAP EBITDA $135M-$145M. ANI continues to expect total company adjusted non-GAAP gross margin between 62% and 63% and the Company will continue to tax effect non-GAAP adjustments for computation of adjusted non-GAAP diluted earnings per share at a tax rate of 26.0%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANIP Upcoming Earnings Report: What to Expect?
- ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences
- ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET
- ANI Pharmaceuticals Financial Report: Key Insights Revealed
- ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension
Questions or Comments about the article? Write to editor@tipranks.com